Farmitalia Carlo Erba S.r.l.

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Fresenius Kabi Oncology Limited

Pharmacia & Upjohn S.p.a.

Antibioticos S.p.a.

Pharmacia S.p.a.

Indena S.p.a.

Alma Mater Studiorum-universitá Di Bologna

Basilea Pharmaceutica Ag

Montedison S.p.a.

Farmitalia Carlo Erba S.p.a.

Istituto Guido Donegani S.p.a.

Dipharma S.p.a.

Olon S.p.a.

Alfasigma S.p.a.

Walter Cabri

Angelo Bedeschi

Ilaria Candiani

Saswata Lahiri

Franco Zarini

Sergio Penco

Govind Singh

Antonio Ricci

Franco Francalanci

Silvia De Bernardinis

Marco Alpegiani

Mauro Marzi

Jacopo Zanon

Fabrizio Giorgi

Claudio Pisano

Paolo Carminati

Giuseppe Giannini

Abul Azim

Nitin Kumar Gupta

Maria Ornella Tinti

Daniele Bianchi

Laura Capolongo

Davide Longoni

Domenico Vergani

Pietro Cesti

Loredana Vesci

Bhuwan Bhaskar Mishra

Domenico Magrone

Nilendu Panda

Giovanni Pozzi

Mario Varasi

Giuseppe Bianchi

Ettore Perrone

Patrizia Ferrari

Alberto Cerri

Franco Zunino

Marcello Marchi

Andrea Gambini

Daniele Ciceri

Mauro Gobbini

Marco Ricci

Patrizia Minetti

Sabrina Dallavalle

Jacopo Roletto

Giorgio Tarzia

Paolo Paissoni

Timo Nuijens

Marco Torri

Maurizio Taddei

Roberto Castagnani

Domenico Alloatti

Tania Cristiano

Andrea Orlandin

Sarbjot Singh Sokhi

Raj Narayan Tiwari

Maneesh Kumar Pandey

Sonu Prasad Shukla

Paolo Ghetti

Ivan Guryanov

Giuseppe Marazzi

Silvia Armaroli

Enrico Siviero

Federico Peterlongo

Gianfranco Battistuzzi

Vinod Singh Tomar

Nikunj Shambhubhai Kachhadia

Fernando Formaggio

Shivaji Haribhau Shelke

Nitin Kumar

Lucia Ferrazzano

Poli Reddy Bhavanam

Barbara Biondi

Krishanu Ray

Markus Heubes

Michael Schleimer

Kumber Singh

Dario Visentini

Madan Singh

Patricio Martin Gomez

Sridhar Reddy Male

Tiziano Martinengo

Saurabh Upadhyay

Suneel Kumar Sharma

Daniele Mario Terrassan

Maria Altamura

Sunil Sanghani

Norberto Gatti

Emanuela Tassoni

Giorgio Fedrizzi

Vishal Handa

Hemant Kumar Singh

Mirella Pilone

Piera Fonte

Luca Domenighini

Nicola Fanto'

Tiziana Brunetti

Daniele Simoni

Sandeep Kumar

Roberto Verga

Ghanashyam Madhukar Sonavane

The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.

Process for the manufacture of degarelix and its intermediates

The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Polymorphic forms of Belinostat and processes for preparation thereof

The invention provides a method for the cleavage of Fmoc group characterized by using a solution comprising 3-(diethylamino)propylamine. In particular, it provides a method for the preparation of peptides in solid phase wherein Fmoc protected amino acids are used and the Fmoc group is cleaved by a solution comprising 3-(diethylamino)propylamine.

Amino deprotection using 3-(diethylamino)propylamine

The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PGmay be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC. 

Process for the preparation of boronic acid esters

The present invention provides an improved process for the preparation of high purity glucagon comprising the use of Xmb-protected amino acids, wherein may Xmb include, e.g., 2,4,6-trimethoxybenzyl, 2,4-dimethoxybenzyl, or 2-hydroxy-4-methoxybenzyl. The process also comprises the use of building blocks such as pseudoprolines to avoid aggregation and obtain the product in high yield and purity.

Process for the preparation of high purity glucagon

The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.

Process for preparing Alectinib or a pharmaceutically acceptable salt thereof

The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer. 

Process for the preparation of ribociclib and its salts

The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.

Process for the manufacture of GLP-1 analogues

The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.

Polymorphic forms of Afatinib free base and Afatinib dimaleate

Process for preparing alectinib or a pharmaceutically acceptable salt thereof

The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib. 

Process for purification of carfilzomib intermediate

Polymorphic forms of belinostat and processes for preparation thereof

The present invention relates to a process for preparing alectinib, or a pharmaceutically acceptable salt thereof, and to related intermediates.

Process for the preparation of alectinib

Growing community of inventors

Rozzano, Italy

Walter Cabri